Dutch packaging company signs a 5-year agreement for the packaging of proprietary bladder cancer detection products
Tjoapack has announced the signing of a 5-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products. Headquartered in the Netherlands, Tjoapack is set to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
Hexvix/Cysview is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCTM with Hexvix/Cysview improves the detection of tumours and leads to more complete resection, less residual tumours and better management decisions.
The contract will see Tjoapack perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
Dexter Tjoa, director corporate strategy at Tjoapack, commented: “Photocure has a global customer base, which comes with many potential challenges. At Tjoapack, we have a huge amount of experience in meeting the demands of multiple markets, especially when it comes to complying with legislation, such as artwork requirements and serialisation.
“In addition, the flexibility offered by our on-site warehousing facility will allow us to ensure continued supply in the shortest possible lead times. We hope this will be the start of a long and successful partnership.”
During the project, Tjoapack will be working with semi-finished stock stored at its facility, only finalising and assembling kits when orders come in.
Commenting on the contract, Gry Stensrud, VP of technical development and operations at Photocure, said: “Photocure delivers transformative solutions to improve the lives of bladder cancer patients. This is very much in line with Tjoapack’s ethos which was a big decision-making factor for us when choosing a partner.
“We were impressed by Tjoapack’s expertise in this area and are confident they’ll be able to meet our requirements.”
Stensrud revealed that Photocure is specifically looking for a supplier who is ready for serialisation. "While our product does not need to be serialised in the US as imaging drugs are exempt there, compliance with the EU FMD is vital to ensure continuous supply to our European markets," he explained.